Artificial intelligence (AI) software developer MaxQ AI has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Accipio Ix software for detecting intracranial hemorrhage.
Accipio Ix is designed to help prioritize the clinical assessment of adult noncontrast head CT studies that show indications of intracranial hemorrhage, according to the vendor. The AI-based software can be integrated natively into CT and PACS networks and installed on premises or via a cloud deployment.
Accipio Ix received the European CE Mark earlier this year.
